Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States

Ranjan Pathak, Smith Giri, Madan Raj Aryal, Paras Karmacharya, Vijaya R Bhatt, Mike G. Martin

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: Febrile neutropenia is a potentially life threatening complication of breast cancer chemotherapy associated with a significant amount of morbidity, mortality, and health care resource utilization. Recent data on the national estimates of mortality rate, length of stay, and health care costs among the subpopulation of febrile neutropenia admissions with breast cancer are lacking.Methods: We used the Nationwide Inpatient Sample database to identify patients with breast cancer hospitalized for febrile neutropenia from 2009 to 2011. We derived data on inhospital mortality rate, length of stay, and mean health care costs and compared it with previous studies.Results: The average inhospital mortality rate during 2009–2011 was 2.6 % (n = 685). Advanced age (≥65 years) was found to be significantly associated with a higher odds of mortality (4.4 vs 1.7 %, OR 2.7, 95 % CI 2.3–3.1, p < 0.01). The mean length of stay was 5.7 days (95 % CI 5.5–5.9 days), whereas the mean cost of hospitalization was $37,087 (95 % CI $34,009–$40,165).Conclusion: Febrile neutropenia-related hospitalizations continue to account for significant morbidity, mortality, and health care resource utilization among patients with breast cancer. Further efforts should be focused on curtailing the rising health care costs without compromising the quality of care.

Original languageEnglish (US)
Pages (from-to)615-617
Number of pages3
JournalSupportive Care in Cancer
Volume23
Issue number3
DOIs
StatePublished - Jan 30 2015

Fingerprint

Febrile Neutropenia
Health Care Costs
Length of Stay
Hospitalization
Breast Neoplasms
Mortality
Patient Acceptance of Health Care
Health Resources
Hospital Mortality
Morbidity
Quality of Health Care
Inpatients
Databases
Costs and Cost Analysis
Drug Therapy

Keywords

  • Breast cancer
  • Febrile neutropenia
  • Quality of care

ASJC Scopus subject areas

  • Oncology

Cite this

Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States. / Pathak, Ranjan; Giri, Smith; Aryal, Madan Raj; Karmacharya, Paras; Bhatt, Vijaya R; Martin, Mike G.

In: Supportive Care in Cancer, Vol. 23, No. 3, 30.01.2015, p. 615-617.

Research output: Contribution to journalArticle

Pathak, Ranjan ; Giri, Smith ; Aryal, Madan Raj ; Karmacharya, Paras ; Bhatt, Vijaya R ; Martin, Mike G. / Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States. In: Supportive Care in Cancer. 2015 ; Vol. 23, No. 3. pp. 615-617.
@article{8a9d4494f8a8456ab653983d934cad67,
title = "Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States",
abstract = "Purpose: Febrile neutropenia is a potentially life threatening complication of breast cancer chemotherapy associated with a significant amount of morbidity, mortality, and health care resource utilization. Recent data on the national estimates of mortality rate, length of stay, and health care costs among the subpopulation of febrile neutropenia admissions with breast cancer are lacking.Methods: We used the Nationwide Inpatient Sample database to identify patients with breast cancer hospitalized for febrile neutropenia from 2009 to 2011. We derived data on inhospital mortality rate, length of stay, and mean health care costs and compared it with previous studies.Results: The average inhospital mortality rate during 2009–2011 was 2.6 {\%} (n = 685). Advanced age (≥65 years) was found to be significantly associated with a higher odds of mortality (4.4 vs 1.7 {\%}, OR 2.7, 95 {\%} CI 2.3–3.1, p < 0.01). The mean length of stay was 5.7 days (95 {\%} CI 5.5–5.9 days), whereas the mean cost of hospitalization was $37,087 (95 {\%} CI $34,009–$40,165).Conclusion: Febrile neutropenia-related hospitalizations continue to account for significant morbidity, mortality, and health care resource utilization among patients with breast cancer. Further efforts should be focused on curtailing the rising health care costs without compromising the quality of care.",
keywords = "Breast cancer, Febrile neutropenia, Quality of care",
author = "Ranjan Pathak and Smith Giri and Aryal, {Madan Raj} and Paras Karmacharya and Bhatt, {Vijaya R} and Martin, {Mike G.}",
year = "2015",
month = "1",
day = "30",
doi = "10.1007/s00520-014-2553-0",
language = "English (US)",
volume = "23",
pages = "615--617",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States

AU - Pathak, Ranjan

AU - Giri, Smith

AU - Aryal, Madan Raj

AU - Karmacharya, Paras

AU - Bhatt, Vijaya R

AU - Martin, Mike G.

PY - 2015/1/30

Y1 - 2015/1/30

N2 - Purpose: Febrile neutropenia is a potentially life threatening complication of breast cancer chemotherapy associated with a significant amount of morbidity, mortality, and health care resource utilization. Recent data on the national estimates of mortality rate, length of stay, and health care costs among the subpopulation of febrile neutropenia admissions with breast cancer are lacking.Methods: We used the Nationwide Inpatient Sample database to identify patients with breast cancer hospitalized for febrile neutropenia from 2009 to 2011. We derived data on inhospital mortality rate, length of stay, and mean health care costs and compared it with previous studies.Results: The average inhospital mortality rate during 2009–2011 was 2.6 % (n = 685). Advanced age (≥65 years) was found to be significantly associated with a higher odds of mortality (4.4 vs 1.7 %, OR 2.7, 95 % CI 2.3–3.1, p < 0.01). The mean length of stay was 5.7 days (95 % CI 5.5–5.9 days), whereas the mean cost of hospitalization was $37,087 (95 % CI $34,009–$40,165).Conclusion: Febrile neutropenia-related hospitalizations continue to account for significant morbidity, mortality, and health care resource utilization among patients with breast cancer. Further efforts should be focused on curtailing the rising health care costs without compromising the quality of care.

AB - Purpose: Febrile neutropenia is a potentially life threatening complication of breast cancer chemotherapy associated with a significant amount of morbidity, mortality, and health care resource utilization. Recent data on the national estimates of mortality rate, length of stay, and health care costs among the subpopulation of febrile neutropenia admissions with breast cancer are lacking.Methods: We used the Nationwide Inpatient Sample database to identify patients with breast cancer hospitalized for febrile neutropenia from 2009 to 2011. We derived data on inhospital mortality rate, length of stay, and mean health care costs and compared it with previous studies.Results: The average inhospital mortality rate during 2009–2011 was 2.6 % (n = 685). Advanced age (≥65 years) was found to be significantly associated with a higher odds of mortality (4.4 vs 1.7 %, OR 2.7, 95 % CI 2.3–3.1, p < 0.01). The mean length of stay was 5.7 days (95 % CI 5.5–5.9 days), whereas the mean cost of hospitalization was $37,087 (95 % CI $34,009–$40,165).Conclusion: Febrile neutropenia-related hospitalizations continue to account for significant morbidity, mortality, and health care resource utilization among patients with breast cancer. Further efforts should be focused on curtailing the rising health care costs without compromising the quality of care.

KW - Breast cancer

KW - Febrile neutropenia

KW - Quality of care

UR - http://www.scopus.com/inward/record.url?scp=84925543134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925543134&partnerID=8YFLogxK

U2 - 10.1007/s00520-014-2553-0

DO - 10.1007/s00520-014-2553-0

M3 - Article

C2 - 25556610

AN - SCOPUS:84925543134

VL - 23

SP - 615

EP - 617

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 3

ER -